Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

[Thromboembolic and bleeding risk assessment in patients with non-rheumatic atrial fibrillation using CHA2DS2-VASc and HAS-BLED scoring systems].

Bozić I, Cvitković I, Carević V, Caljkusić K, Trgo G, Fabijanić D.

Lijec Vjesn. 2013 Mar-Apr;135(3-4):86-91. Review. Croatian.

PMID:
23671975
2.

Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.

Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A.

Am J Med. 2014 Oct;127(10):979-986.e2. doi: 10.1016/j.amjmed.2014.05.003. Epub 2014 May 13.

PMID:
24838192
3.

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

Friberg L, Rosenqvist M, Lip GY.

Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.

PMID:
22246443
4.

Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?

Bratland B, Hornnes MB.

Tidsskr Nor Laegeforen. 2014 Jan 28;134(2):175-9. doi: 10.4045/tidsskr.13.0626. English, Norwegian.

5.

Can we predict stroke in atrial fibrillation?

Lip GY.

Clin Cardiol. 2012 Jan;35 Suppl 1:21-7. doi: 10.1002/clc.20969. Review.

6.

Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.

Guo Y, Lip GY, Apostolakis S.

Hosp Pract (1995). 2013 Feb;41(1):71-8. doi: 10.3810/hp.2013.02.1012. Review.

PMID:
23466969
7.

Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.

Apostolakis S, Lane DA, Buller H, Lip GY.

Thromb Haemost. 2013 Nov;110(5):1074-9. doi: 10.1160/TH13-07-0552. Epub 2013 Sep 19.

PMID:
24048467
8.

The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.

Barnes GD, Gu X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Besley D, Krol GD, Froehlich JB, Kaatz S.

Thromb Res. 2014 Aug;134(2):294-9. doi: 10.1016/j.thromres.2014.05.034. Epub 2014 Jun 2.

PMID:
24929840
9.

Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.

Zhu WG, Xiong QM, Hong K.

Tex Heart Inst J. 2015 Feb 1;42(1):6-15. doi: 10.14503/THIJ-14-4353. eCollection 2015 Feb. Review.

10.

CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Puurunen MK, Kiviniemi T, Schlitt A, Rubboli A, Dietrich B, Karjalainen P, Nyman K, Niemelä M, Lip GY, Airaksinen KE.

Thromb Res. 2014 Apr;133(4):560-6. doi: 10.1016/j.thromres.2014.01.007. Epub 2014 Jan 11.

PMID:
24461143
11.

WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001938. Review.

PMID:
17636690
12.

Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.

Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, Bass EB.

Cochrane Database Syst Rev. 2001;(1):CD001938. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD001938.

PMID:
11279741
13.

[Nonvalvular atrial fibrillation: data from the Observatory of Cardiovascular Diseases in the province of Trieste (Italy)].

Mazzone C, Carriere C, Grande E, Iorio AM, Barbati G, Zecchin M, Serdoz LV, Cioffi G, Tarantini L, Sinagra G, Scardi S, Di Lenarda A.

G Ital Cardiol (Rome). 2015 Jun;16(6):361-72. doi: 10.1714/1934.21032. Italian.

PMID:
26156697
14.

[Atrial fibrillation and stroke].

Aamodt AH, Sandset PM, Atar D, Tveit A, Russell D.

Tidsskr Nor Laegeforen. 2013 Aug 6;133(14):1453-7. doi: 10.4045/tidsskr.12.0850. Review. Norwegian.

15.

Patients with atrial fibrillation and CHA2DS2-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!".

Patti G, Cavallari I.

Heart Rhythm. 2015 Dec;12(12):2515-20. doi: 10.1016/j.hrthm.2015.07.017. Epub 2015 Jul 15. Review.

PMID:
26188249
16.

[Risk stratification for thromboembolism and antithrombotic prophylaxis in atrial fibrillation].

Di Pasquale G, Riva L.

G Ital Cardiol (Rome). 2012 Nov;13(11 Suppl 1):11S-18S. doi: 10.1714/1179.13062. Italian.

PMID:
23160015
17.

[Anticoagulation in atrial fibrillation. Strategies in special situations].

Volkmann H, Walter M, Walter C, Vetter S.

Clin Res Cardiol Suppl. 2011 May;6:58-65. Review. German.

PMID:
22528179
18.

Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.

Volterrani M, Iellamo F, Rosano G, Guarini P, Pusineri E, Bonassi S, Chimini C, Zaccà F, Proto C; SICOA (Società Italiana Cardiologia Ospedalità Accreditata) Investigators.

Int J Cardiol. 2013 Oct 12;168(5):4729-33. doi: 10.1016/j.ijcard.2013.07.169. Epub 2013 Jul 26.

PMID:
23948115
19.

AFib in special populations.

French WJ.

Am J Med. 2014 Apr;127(4):e17-8. doi: 10.1016/j.amjmed.2013.06.005.

PMID:
24655745
20.

[Thromboembolic risk in atrial fibrillation: new clinical perspectives].

Villani GQ, Andreoli AM, Villani M, Capucci A.

G Ital Cardiol (Rome). 2008 Oct;9(10 Suppl 1):22S-26S. Italian.

PMID:
19195302

Supplemental Content

Support Center